Global healthcare leader Abbott announced Thursday that it has reached a $23 billion deal to acquire Exact Sciences.
We are transferring coverage of Exact Sciences EXAS, keeping our moat rating at none and raising our fair value estimate to $78 per share from $68 previously. This is driven by a more optimistic view ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback